Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly and Company (NYSE: LLY) faced a sharp setback on Monday as HSBC issued a rare double downgrade, slashing its rating ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Eli Lilly alleges that each company is selling illegal knockoffs ... the active ingredient in both Zepbound and Mounjaro. Mounjaro surged in popularity after it was approved to treat diabetes ...